Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients

A Randomized, Double-blind, Placebo Controlled, Phase IIA Study to Assess the Effect on Gastroesophageal Reflux Disease (GERD) Symptoms, Pharmacokinetics, Safety and Tolerability of 4 Weeks Treatment With AZD3355 65 mg Bid as add-on Treatment to a Proton Pump Inhibitor (PPI) in Patients With an Incomplete Response to PPI.

The purpose of this study is to estimate the effect of AZD3355 as an add-on treatment to a Proton Pump Inhibitor (PPI) on Gastroesophageal reflux disease (GERD) symptoms in patients with an incomplete response to PPI treatment.

Inclusion Criteria:

• Provision of written informed consent
• At least 6 months history of Gastroesophageal reflux disease (GERD) symptoms
• Continuous treatment with Proton Pump Inhibitor (PPI)
• Ability to read and write

Exclusion Criteria:

• Prior surgery of the upper gastrointestinal (GI) tract
• History of clinically significant diseases other than GERD
• Need for concomitant medication with drugs that may influence gastrointestinal symptoms